News
Latest news
Synnovation Announces First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors

Business Wire

February 24 2025
Kailera Launches With $400M Series A And Clutch Of Chinese Obesity Drugs

Fierce Biotech

October 01 2024
CG Oncology Follows Big IPO With New Results For Bladder Cancer Drug

BioPharma Dive

May 03 2024
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

CG Oncology

February 27 2024
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CG Oncology

January 30 2024
Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO

Yahoo! Finance

January 26 2024

Get In Touch

Contact Us